Clinical study of autoimmune hepatitis: A single center study at National Liver Institute

Om Kolsoum Mohamed Alhaddad; Khalid Gamel; Maha Mohamed Elsabaawy; Asmaa Ibrahim Gomaa; Tamer Samir; Fatma Salah El din Abdel Mageed

doi:10.53730/ijhs.v7nS1.14650

Authors

Om Kolsoum Mohamed Alhaddad Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Egypt
Khalid Gamel Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Egypt
Maha Mohamed Elsabaawy Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Egypt
Asmaa Ibrahim Gomaa Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Egypt
Tamer Samir Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Egypt
Fatma Salah El din Abdel Mageed Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Egypt

Keywords:

autoimmune, Crohn’s disease, liver biopsy, hepatitis

Abstract

Introduction: Autoimmune hepatitis (AIH) is an infrequent liver insult with notorious comorbidities, in which autoimmune-mediated relativities against hepatocytes are thought to play a crucial role. Aim: to delineate updated demographics of AIH. Methods: This study was conducted retrospectively. Assessment included demographic, laboratory, radiological, and histopathological characteristics (if feasible). Results: The mean age of the studied cases was 34.63 ± 12.76 years with minimum 19 years and maximum 65 years with female predominance as There were 15 males (26.3%) and 42 females (73.7%). 15.8% of cases had AIH associated DM, 2.2% with autoimmune thyroiditis, and 1.5% with Crohn’s disease. Conclusion: AIH is a prevalent liver disease.

Downloads

Download data is not yet available.

References

Manns, M.P., Lohse, A.W., & Vergani, D. (2015). Autoimmune hepatitis–update 2015. Journal of hepatology, 62(1), S100-S111.

Kim, B.H., Choi, H.Y., Ki, M., Kim, K.-A., Jang, E.S., & Jeong, S.-H. (2017). Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea. PloS one, 12(8), e0182391.

Tanaka A, Mori M, Matsumoto K, Ohira H, Tazuma S, Takikawa H. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res 2019; 49:881-889.

Grønbæk L, Vilstrup H, Pedersen L, Christensen K, Jepsen P. Family occurrence of autoimmune hepatitis: a Danish nationwide registry-based cohort study. J Hepatol 2018; 69:873-877.

Heneghan, M.A. (2022a). Overview of autoimmune hepatitis. In S. Chopra & K. M. Robson (Eds.), UpToDate. Online: Wolters Kluwer.

Fallatah, H. I., Akbar, H. O., & Qari, Y. A. (2010). Autoimmune hepatitis: Single-center experience of clinical presentation, response to treatment and prognosis in Saudi Arabia. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association, 16(2), 95.

Mogahed, E., El-Karaksy, H., Zaki, H., & Abdullatif, H. (2022). Autoimmune hepatitis in Egyptian children: A single center experience. International Journal of Immunopathology and Pharmacology, 36, 20587384211073265.

Aljumah, A. A., Al-Ashgar, H., Fallatah, H., & Albenmousa, A. (2019). Acute onset autoimmune hepatitis: Clinical presentation and treatment outcomes. Annals of Hepatology, 18(3), 439-444.

Koay, L. B., Lin, C. Y., Tsai, S. L., Lee, C., Lin, C. N., Sheu, M. J., ... & Sun, C. S. (2006). Type 1 autoimmune hepatitis in Taiwan: diagnosis using the revised criteria of the International Autoimmune Hepatitis Group. Digestive diseases and sciences, 51, 1978-1984.

Kronzer VL, Bridges SL Jr, Davis JM 3rd.Why women have more autoimmune diseases than men: An evolutionary perspective. Evol Appl. 2020 Dec 1;14(3):629-633.

Buechter, M., Dorn, D., Möhlendick, B., Siffert, W., Baba, H. A., Gerken, G., & Kahraman, A. (2023). Characteristics and Long-Term Outcome of 535 Patients with Autoimmune Hepatitis—The 20-Year Experience of a High-Volume Tertiary Center. Journal of Clinical Medicine, 12(13), 4192.

Tamimi, T. A., Sallam, M., Rayyan, D., Farah, R., Alkhulaifat, D., Al-Ani, A., ... & Rayyan, Y. (2023). Clinical Characteristics of Autoimmune Hepatitis in a Middle Eastern Population: A Tertiary Care Center Experience. Journal of Clinical Medicine, 12(2), 629.

Beinhardt, S., Eder, M., Halilbasic, E., Trauner, M., & Hofer, H. (2013). Clinical presentation and outcome of patients with autoimmune hepatitis: a single center experience. Zeitschrift für Gastroenterologie, 51(05), A3.

Joshita, S., Yoshizawa, K., Umemura, T., Ohira, H., Takahashi, A., Harada, K., ... & Japan Autoimmune Hepatitis Study Group (JAIHSG). (2018). Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey. Journal of Gastroenterology, 53, 1079-1088.

Yeoman, A.D., Westbrook, R.H., Zen, Y., Bernal, W., Al-Chalabi, T., Wendon, J.A., et al. (2014). Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. Journal of hepatology, 61(4), 876-882.

Werner, M., Wallerstedt, S., Lindgren, S., Almer, S., Björnsson, E., Bergquist, A., ... & Danielsson, Å. (2010). Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scandinavian journal of gastroenterology, 45(4), 457-467.

Liu, L., Cao, J., Zhong, Z., Guo, Z., Jiang, Y., Bai, Y., & Xu, J. (2019). Noninvasive indicators predict advanced liver fibrosis in autoimmune hepatitis patients. Journal of Clinical Laboratory Analysis, 33(7), e22922.

Hennes, E.M., Oo, Y.H., Schramm, C., Denzer, U., Buggisch, P., Wiegard, C., et al. (2008). Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Official journal of the American College of Gastroenterology| ACG, 103(12), 3063-3070.

Fujita, K., Oura, K., Tadokoro, T., Nakahara, M., Tani, J., Morishita, A., ... & Masaki, T. (2021). Prognosis of probable autoimmune hepatitis patients: a single-center study in Japan. Internal and Emergency Medicine, 1-8.

Montano‐Loza, A. J., Carpenter, H. A., & Czaja, A. J. (2007). Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end‐stage liver disease. Hepatology, 46(4), 1138-1145.

Xu, Q., Sheng, L., Bao, H., Chen, X., Guo, C., Li, H., ... & Hua, J. (2017). Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis. Journal of gastroenterology and hepatology, 32(3), 639-644.

Li, Y., Yan, L., Wang, R., Wang, Q., You, Z., Li, B., ... & Ma, X. (2021). Serum Immunoglobulin G levels predict biochemical and histological remission of autoimmune hepatitis Type 1: a single-center experience and literature review. Clinical Reviews in Allergy & Immunology, 1-9.

MOHAMED, A. K., MAHMOUD, H. A., MORAD, M., & WESAM, S. (2020). Comparison between Different Risk Scores in Predicting Hospital Mortality for Patients with Decompensated Liver Cirrhosis: A Single Center Study. The Medical Journal of Cairo University, 88(June), 1247-1255.